Vericel

VCELNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$2.309 B

$45.09 +0.76%

Close of 7 Aug 2026

Revenue

$276.3M

#2174 by revenue

Earnings

$16.5M

#1941 by earnings

Shares outstanding

51,206,614

Latest filing cover page

P/E ratio

139.8

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#31Biocryst PharmaceuticalsBCRX$2.40B
#32Hemab TherapeuticsCOAG$2.32B
#33VericelVCEL$2.31B
#34Adma BiologicsADMA$2.22B
#35MesoblastMESO$2.06B

Where these numbers come from

Share counts and financials for Vericel are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.